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Abstract 
Background: Malaria antibody responses measured at delivery have been associated with protection from maternal 
anaemia and low birth weight deliveries. Whether malarial antibodies present in the first half of pregnancy may pro-
tect from these or other poor birth outcomes is unclear. To determine whether malaria antibodies in the first half of 
pregnancy predict pregnancy outcomes, antibodies were measured to a range of merozoite antigens and to antigens 
expressed on the surface of parasitized red blood cells (pRBCs) in plasma samples collected at 14–20 weeks of gesta-
tion from Malawian women. The latter antibodies were measured as total IgG to pRBCs, and antibodies promoting 
opsonic phagocytosis of pRBCs. Associations between antibodies and maternal haemoglobin in late pregnancy or 
newborn size were investigated, after adjusting for potential covariates.
Results: Antibodies to pRBC surface antigens were associated with higher haemoglobin concentration at 36 weeks. 
Total IgG to pRBCs was associated with 0.4 g/l [(95% confidence interval (0.04, 0.8)] increase in haemoglobin, and 
opsonizing antibody with 0.5 (0.05, 0.9) increase in haemoglobin for each 10% increase in antibody. These antibod-
ies were not associated with birthweight, placental malaria, or newborn anthropometrics. Antibodies to merozoite 
antigens and non-placental-binding IEs were not associated with decreased risk of any of these outcomes. In some 
instances, they were negatively associated with outcomes of interest.
Conclusion: Antibodies to placental-binding infected erythrocytes may be associated with higher haemoglobin 
levels in pregnancy, whereas antibodies to other malaria antigens may instead be markers of malaria exposure.
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Background
Malaria in pregnancy accounts for an estimated 10,000 
maternal and 200,000 infant deaths per year worldwide 
with over 25 million pregnancies at risk of infection 
in sub-Saharan Africa alone [1], and is predominantly 
caused by Plasmodium falciparum. Many of the associ-
ated deaths are due to severe maternal anaemia and low 
birth weight (LBW) [2]. Peripheral blood P. falciparum 
infections generally peak between 13 and 18 gestation 
weeks, which is when parasitized red blood cells (pRBCs) 
begin to sequester in the placenta [3, 4]. Placental adher-
ence of pRBCs is mediated by the interaction between 
the pregnancy-related variant surface antigen (VSA) 
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VAR2CSA expressed on the surface of the pRBC and 
chondroitin sulphate A (CSA) receptors expressed by the 
placental syncytiotrophoblast [5, 6]. With repeated preg-
nancies, women acquire antibodies to pRBCs that express 
VAR2CSA and develop protection against infection [7, 
8], that is associated with improved pregnancy outcomes 
[9, 10]. By contrast, antibodies to non-pregnancy-related 
malaria antigens (merozoite antigens, schizonts and non-
pregnancy-specific VSA) have shown little association 
with pregnancy outcomes [11–13].
Women who are parasitaemic at first antenatal care visit 
may have an increased risk of adverse outcomes such as 
LBW, placental infection, preterm birth and anaemia [14–
17]. It is possible that measures of malaria immunity at this 
point could be used to identify women at relatively high 
risk of poor pregnancy outcomes. Most studies to date but 
not all [18–20] have investigated the relationship between 
immunity measured at or close to delivery with pregnancy 
outcomes. While relevant to defining the potential protec-
tive role of malaria immunity in pregnancy outcomes, such 
studies would not allow health workers to identify women 
at high or low risk of such outcomes in a timely way, to 
allow them to offer tailored malaria prevention strate-
gies. If only a proportion of pregnant women are at high 
risk, and these women could be identified at first antenatal 
attendance, malaria preventive strategies could be targeted 
to those lacking protection and at greatest need.
Acquisition of antibodies is dependent on a number 
of factors such as maternal age, gravidity and presence 
of other infections such as HIV [7, 21, 22]. In addition, 
malaria infection, HIV and gravidity have been shown 
to modify the effects of the association between malaria 
immunity and pregnancy outcomes [12, 23]. Malaria pre-
vention strategies such as indoor residual spraying, insec-
ticide-treated bed nets (ITNs) and intermittent preventive 
treatment in pregnancy (IPTp) are designed to reduce the 
exposure to malaria and improve pregnancy outcomes, 
but may impair acquisition of immunity [24]. These fac-
tors must be considered when determining the relation-
ship between malaria immunity and pregnancy outcomes.
Pregnant women residing in malaria-endemic regions 
often suffer from undernutrition as a result of poverty, 
seasonal variation in food availability and poor intake of 
micronutrients, which significantly impact their health 
and pregnancy outcomes. It was hypothesized that among 
Malawian women enrolled in a nutrient supplementation 
study, one or more measures of naturally acquired malaria 
antibody, taken at first antenatal visit, would be associated 
with protection from adverse pregnancy outcomes such 
as maternal anaemia, evidence of malaria on placental 
histology, or measures of fetal growth in utero.
Methods
Study context
From February 2011 to August 2012 one thousand three 
hundred and ninety-one pregnant women were enrolled 
in the iLiNS-DYAD-M randomized controlled trial, 
which evaluated whether home fortification of pregnant 
women’s diets with nutrient supplements could increase 
birth size. Participants received either iron and folic acid 
supplements, a multiple micronutrient capsule, or 20  g 
of lipid-based nutrient supplementation each day from 
enrolment, from 14 to 20 completed weeks of gestation, 
until delivery. Dating ultrasounds were performed at 
enrolment to determine gestation at delivery. All partici-
pants received 2 doses of sulfadoxine-pyrimethamine (SP, 
Fansidar®). The trial design, details of the nutrient sup-
plements, and main findings have been published else-
where [25, 26]; the type of nutrient supplementation did 
not affect maternal anti-malarial antibodies, or suscepti-
bility to malaria. Maternal haemoglobin at 36 gestation 
weeks (gw) and birth weight, gestational age and infant 
length at delivery were measured, and placental histology 
was examined.
Peripheral venous blood samples were collected at 
enrolment and at 36 gw. Only samples collected at enrol-
ment with a paired 36 gw sample were selected for anal-
ysis. Samples were not available at 36 gw from women 
who did not attend this visit, women who had already 
delivered, and women from whom blood was not avail-
able for other logistical reasons. After exclusion of eight 
sets of twins, all available pairs of samples were assayed. 
Blood plasma was separated at each time point and 
stored frozen at −80 °C before shipping to Australia for 
measurements of anti-malarial immunity. Malaria para-
sitaemia was determined using blood film microscopy, 
rapid diagnostic test (RDT), polymerase chain reaction 
(PCR), and placental histology at delivery. Placental 
malaria (PM) was categorized as active infection (pres-
ence of pRBCs with or without haemozoin in mono-
cytes and/or fibrin); past infection (haemozoin without 
pRBCs); or no infection, based on placental histology. 
Due to the low numbers of active placental infections 
(n = 31), only past placental infection and no infection 
were compared.
Ethics approval
Ethical approval for the trial and the laboratory work was 
granted by the College of Medicine Research and Ethics 
Committee of Malawi, and by Tampere University Hos-
pital Ethics Committee, Finland. The Melbourne Health 
Human Research Ethics Committee approved the labora-
tory work performed for the study.
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Parasite and cell culture
Plasmodium falciparum isolates CS2 and E8B were 
selected as representatives of placental-binding and 
non-placental-binding parasite isolates. CS2 binds 
to CSA expressed on the placenta while E8B binds 
to endothelial receptors CD36 and ICAM-1 [27, 28]. 
Parasite cultures were maintained as described in 
[29]. Pre-monocytic THP-1 cells were cultured for 
the opsonic phagocytosis assay and maintained as 
described in [30].
Measurement of IgG and opsonizing antibodies to VSA 
expressed by placental‑binding and non‑placental‑binding 
parasite isolates
Plasma samples from women who had samples available 
from study enrolment and at 36 gw were used to meas-
ure antibody levels. Flow cytometry based immunoassays 
were performed as previously described [25] to deter-
mine relative levels of naturally-acquired IgG to VSA 
expressed by the parasite isolates described above, and 
to measure levels of antibodies that opsonize pRBC for 
phagocytosis by THP-1 cells. Plasma was assayed at 1:20 
dilution (IgG to VSA) or 1:10 (opsonizing antibodies). 
For both types of assay, antibody levels were reported as 
a percentage of the positive controls where the positive 
controls were a pool of human plasma with known high 
levels of antibody to VSA antigens. Positivity for each 
antigen was calculated as mean plus three standard devi-
ations of the fluorescence intensity of 30 different nega-
tive controls.
Measurement of IgG to merozoite antigens and schizont 
extract via fluorescent immunosorbent assay
Recombinant merozoite antigens MSP1 19kD, MSP2, 
MSP3, PfRh2 (construct PfRh2-2030) (6088–7584  bp) 
and EBA175 (region III-V) were prepared as detailed 
[25]. A fluorescent immunosorbent assay was designed to 
measure IgG to merozoite antigens as described in [25] 
and the IgG levels were reported as a percentage of the 
positive control, where the positive control was a pool of 
human plasma collected from individuals with immunity 
to malaria.
Statistical methods
The outcome variables of interest included maternal hae-
moglobin levels (g/l, continuous) at 36 gw; past placental 
malaria (PM) compared to no placental malaria; birth-
weight (in grams, continuous variable); small for gesta-
tional age (SGA: binary variable defined as birthweight 
below the 10th centile on the United States national ref-
erence scale for fetal growth [31]), stunting: length-for-
age Z-score (LAZ)  <−2 at birth (binary variable); and 
small head circumference (HCZ <−2).
The selected covariates included gravidity, maternal 
age, HIV, bed net use, body mass index (BMI) at enrol-
ment, malaria microscopy at enrolment, socioeconomic 
status (SES), study site, season at enrolment and supple-
mentation group, and were recorded as described [25]. 
These covariates were chosen based on their effects on 
malaria antibody levels and pregnancy outcomes in the 
cohort, or their previously-demonstrated biological rel-
evance to the association between antibody levels and 
pregnancy outcomes. Gravidity groups were categorized 
as primi, secundi and multigravidae. Maternal age was 
categorized as <21, 21–25, 26–30 and >30 years. Mater-
nal BMI at enrolment was categorized into low (<18.5 kg/
m2), normal (18.5–25  kg/m2) and increased (>25  kg/
m2). The SES was calculated based on a household assets 
adjusted z-score (HHAZ) system [32], where a partici-
pant with a HHAZ below the median (z-score = −0.387) 
were considered as having a low SES. HIV, malaria infec-
tion, seasons at enrolment (rainy and dry) and ITN use 
were incorporated as dichotomous variables. Study sites 
(Lungwena, Malindi, Namwera and Mangochi) and sup-
plementation groups (IFA, MMN and LNS) were used as 
categorical variables.
Statistical analyses of the relationship between antibody 
levels and pregnancy outcomes after adjusting 
for covariates
Statistical analyses were performed using STATA 13.0 
version (StataCorp LP, Texas, USA). Differences in the 
characteristics between the participants included and 
excluded in the study were determined by performing 
a Student’s t test for normally distributed variables or 
Mann–Whitney U test for non-normally distributed vari-
ables, or test of proportion for categorical variables.
Univariate and multivariate linear or logistic regression 
analysis were performed as appropriate to assess the rela-
tionship between antibody levels at enrolment and preg-
nancy outcomes adjusting for the covariates described 
above. Antibody levels were treated as continuous vari-
ables or as categorical variables following categorization 
into low, middle and high antibody tertiles.
Results
Study participants
Following exclusion of twins, antibody determination 
was performed for plasma samples collected from 1002 
participants at enrolment who also had a sample at 36 
gw. Among participants with samples at 36 gw, only 2.8% 
had preterm births.
Socio-demographic characteristics and birth outcome 
differences between iLiNS study participants who were 
included and excluded from the present analyses were 
determined (Table  1). Women included in the analyses 
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were similar to those excluded in the analysis in age, HIV 
prevalence, SES and BMI. However women who were 
excluded had shorter pregnancies (because only women 
with 36 gestation week data available were included), 
more frequently delivered children with low birthweight, 
were more likely to be in their first pregnancy, and less 
likely to use ITNs compared to those who were included. 
Among included women, 10% had malaria infection 
detected by microscopy and 25% by PCR at enrolment 
(Table 1).
Associations between malaria antibody at enrolment 
and maternal haemoglobin concentration at 36 weeks 
and birth weight
Median haemoglobin levels at 36 gw were 110  g/l (IQR 
101–120; Table  1). After adjustment for covariates 
including gravidity and malaria at enrolment, there was 
a statistically significant positive association between 
antibodies measured before 20 gestation weeks to pla-
cental-binding VSA and haemoglobin concentration; 
with every 10% increase in antibody levels the haemo-
globin concentration at 36 gw increases by 0.5  g/l (95% 
CI 0.05, 0.9; p = 0.029) for IgG to placental-binding VSA 
and 0.4 g/l (0.04, 0.8; p = 0.030) for opsonic phagocytosis 
activity of antibodies to placental-binding VSA (Table 2). 
The median levels of antibodies to placental-binding 
VSA and of opsonic phagocytosis activity of antibodies 
were 15.0 and 32.7% of positive controls, respectively. In 
contrast, antibodies to MSP1 19kD, MSP2, EBA175 and 
schizont extract were negatively associated with haemo-
globin levels at 36  weeks (coefficients −0.5 to −1.3  g/l, 
0.003 < p<0.032; Table 2). There was no statistically sig-
nificant association between levels of antibodies to the 
non-placental-binding line, or to recombinant MSP3 or 
Rh2A9, and maternal haemoglobin concentration.
In adjusted analyses, antibodies to none of the targets 
examined were significantly associated with birthweight; 
differences attributable to each 10% increase in antibody 
ranged up to 13 g (Table 2).
Association between malaria antibody at enrolment 
and placental malaria, small for gestational age and low 
length‑for‑age
To examine relationships between antibody immunity and 
categorical outcomes, antibody responses were divided 
into three equal-sized groups, high, medium and low.
Table 1 Comparison of characteristics of the participants included and excluded in the analysis
Data presented as mean (SD), median (IQR) or number (proportion of women as a percentage) for women included and excluded in the study, allowing for missing 
observations for each variable
SD, standard deviation; IQR, interquartile range; BMI, body mass index; HIV, human immunodeficiency virus; Hb, haemoglobin; SGA, small for gestational age; PCR, 
polymerase chain reaction
Characteristic Included (n = 1002) Excluded (n = 377) p value
Gestation weeks at delivery, mean (SD) 39.8 (1.5) 37.0 (4.9) <0.0001*
Maternal age, years, mean (SD) 24.5 (5.8) 25.3 (6.1) 0.214
Gravidity, number (%)
 Primigravidae 199 (19.9%) 104 (27.6%) 0.002*
 Secundigravidae 201 (20.1%) 80 (21.2%) 0.630
 Multigravidae 600 (59.9%) 192 (50.9%) 0.003*
Low socio-economic status, number (%) 554 (55.7%) 162 (50.9%) 0.135
BMI at enrolment, median (IQR), kg/m2 21.6 (20.3, 23.5) 22.1 (20.4, 23.7) 0.063
HIV infected, number (%) 129 (13.0%) 52 (15.9%) 0.186
Maternal haemoglobin levels at 36 gw, median (IQR), g/l 110 (101, 120) 115 (106, 123) 0.052
Prevalence of anaemia at 36 gw (Hb <100 g/l), number (%) 200 (20.9%) 12 (14.5%) 0.165
Birthweight, mean (SD), g 3011 (412.8) 2791 (536.5) <0.0001*
Prevalence of low birthweight, <2500 g 96 (10.3%) 51 (23.8%) <0.0001*
Prevalence of SGA, number (%) 255 (30.6%) 54 (29.0%) 0.668
Microscopy at enrolment, number (%) 107 (10.7%) 39 (10.4%) 0.872
PCR positivity for malaria at enrolment, number (%) 245 (25.0%) 111 (30.2%) 0.054
PCR positivity for malaria at 36 gw, number (%) 92 (9.3%) 4 (5.1%) 0.212
Placental malaria
 Active infection 31 (3.8%) 11 (5.6%) 0.257
 Past infection 293 (36.0%) 55 (28.1%) 0.037*
 Uninfected 489 (60.1%) 130 (66.3%) 0.110
ITN use at enrolment, number (%) 399 (72.0%) 122 (59.5%) 0.001*
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Because few women (31, 4%) had active placental 
malaria, the analysis compared only past PM (present in 
36%) to no PM. In adjusted analyses, pregnant women in 
the high antibody tertile for MSP2 were more likely to 
have past PM than those in the low antibody tertile, OR 
1.83 (95% CI 1.01, 3.31; p = 0.046) (Table 3). There were 
odds ratios of similar magnitude for high compared to 
low levels of opsonizing antibodies to the placental-bind-
ing and non-placental-binding parasite lines and high 
compared to low levels of antibody to schizont extract 
at enrolment but these associations were not statistically 
significant (Table 3).
In adjusted analyses, antibodies to none of the targets 
examined were significantly associated with being born 
SGA (Table 4). Women in the middle tertile for opsoniz-
ing antibody to placental-binding VSA had a signifi-
cantly higher risk of LAZ  <−2, RRR 2.25 (95% CI 1.14, 
4.42) than women in the low tertile group, but this was 
not observed in comparisons of high versus low antibody 
comparisons (OR 1.14 95%CI 0.53, 2.47) (Table  4). No 
other significant associations were found, and the OR for 
other associations was small.
Discussion
This study tested the hypothesis that measures of malaria 
antibody immunity at first antenatal visit could predict 
pregnancy outcomes in Malawian women enrolled in 
the iLiNS-DYAD-M clinical trial. In 1002 women, the 
study showed that IgG to VSA and antibodies promot-
ing opsonic phagocytosis of pRBCs of placental-binding 
parasite isolates were associated with higher maternal 
haemoglobin levels at 36 gw. These measures of preg-
nancy-specific malaria immunity were not significantly 
associated with birthweight or SGA in adjusted analy-
ses. Antibodies to other malaria antigens assessed either 
demonstrated no significant associations or negative 
associations with the pregnancy outcomes assessed. 
Antibodies to merozoite antigens MSP1 19kD, MSP2, 
EBA175 and schizont extract were associated with lower 
haemoglobin concentration at 36  weeks and antibodies 
to MSP2 were associated with an increased likelihood of 
past PM. The study was performed in women receiving 
recommended doses of IPTp and ITNs, and investigated 
potential additional benefits of antibody immunity on 
outcomes.
The positive associations between both IgG and 
opsonizing antibodies to placental-binding isolate VSA 
and haemoglobin levels at 36 gw are in agreement with 
previous observations in pregnant women from Blantyre, 
Malawi [33, 34] and Kilifi, Kenya [35], although two of 
these studies examined antibody responses only at term. 
By contrast, IgG to VSA of a placental-binding isolate, 
measured (like this study) in samples collected in first 
half of pregnancy, was not associated with haemoglobin 
concentrations in a previous clinical trial in Lungwena, 
Malawi [18]. In that study, antibody responses were 
measured in 549 women (about half the present study), 
and the study lacked statistical power to detect modest 
associations. Maternal anaemia may increase the risk of 
preterm births [36] and interferes with fetal growth caus-
ing LBW [2, 37]. Although the haemoglobin concentra-
tion was only 0.4–0.5 g/l higher with every 10% increase 
in antibody levels (so a woman with antibody level 100% 
of controls is expected to have a haemoglobin 5 g/l higher 
than a matched woman with no antibody) the positive 
association observed in the current cohort suggests a 
Table 2 Association between the participants’ malaria antibody levels at enrolment and their blood haemoglobin con-
centration at 36 gestation weeks and their child’s birthweight
Analysis for each individual antibody was adjusted for gravidity, maternal age, HIV, ITN use, body mass index at enrolment, malaria microscope positivity at enrolment, 
socioeconomic status, study site, season at enrolment and supplementation groups. Results show increase in haemoglobin or birth weight per 10% increase in 
antibody
95% CI, 95% confidence interval; IgG, immunoglobulin G; VSA, variant surface antigens, MSP, merozoite surface protein; EBA175, erythrocyte binding homologue 175; 
PfRh2, Plasmodium falciparum reticulocyte binding homologue 2
Antibody type Haemoglobin concentration (g/l) Birthweight (g)
Coefficient (95% CI) p value Coefficient (95% CI) p value
IgG to placental-binding VSA 0.5 (0.05, 0.9) 0.029* −9.7 (−21.5, 2.1) 0.106
Opsonising antibodies to placental-binding VSA 0.4 (0.04, 0.8) 0.030* 2.0 (−9.0, 13.0) 0.721
Opsonising antibodies to non-placental-binding VSA 0.2 (−0.3, 0.6) 0.476 −3.1 (−16.4, 10.2) 0.651
MSP1 19kD −0.7 (−1.3, −0.1) 0.018* 9.4 (−7.8, 26.6) 0.283
MSP2 −0.7 (−1.2, −0.1) 0.017* 5.2 (−10.3, 20.8) 0.507
MSP3 −0.2 (−0.7, 0.4) 0.592 −13.2 (−29.7, 3.3) 0.115
EBA175 −1.1 (−1.7, −0.4) 0.003* 5.3 (−14.0, 24.5) 0.589
PfRh2 −0.2 (−0.8, 0.5) 0.604 −8.6 (−27.3, 10.0) 0.364
Schizont extract −0.5 (−0.10, −0.05) 0.032* 3.1 (−10.1, 16.2) 0.648
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potential role of these antibodies in preventing malaria-
induced anaemia.
The associations between levels of antibodies to some 
merozoite proteins or to schizont extract and risk of 
anaemia suggest that some of these antibodies may be 
acting as markers of previous malaria infection, rather 
than predictors of better pregnancy outcomes. Anti-
bodies to merozoite antigens are well known to increase 
with exposure [38]. Repeated malaria episodes will lead 
to cumulative destruction of RBCs and lower haemoglo-
bin levels. SES was strongly associated with malaria risk 
(likely to be correlated with exposure, e.g. through poor 
housing) and was adjusted for in the analysis, but there 
may be other factors that affected malaria and anae-
mia risk in this group which were not identified and so 
not adjusted for, such as location and characteristics of 
Table 3 Association between antibody tertiles at enrolment and odds of past placental malaria
Data presented as odds ratio (95% confidence interval). Multivariate logistic regression analysis performed to determine the risk of past PM between pregnant 
women in the middle antibody tertile compared to women in the low antibody tertile. Analysis adjusted for gravidity, maternal age, HIV, ITN use, body mass index at 
enrolment, malaria microscopy at enrolment, socioeconomic status, study site and supplementation groups
OR, odds ratio, 95% CI, 95% confidence interval; IgG, immunoglobulin G; VSA, variant surface antigens, MSP, merozoite surface protein; EBA175, erythrocyte binding 
homologue 175; PfRh2 Plasmodium falciparum reticulocyte binding homologue 2
Antibody type Past placental malaria
Middle compared to low antibody tertile High compared to low antibody tertile
OR (95% CI) p value OR (95% CI) p value
IgG to placental-binding VSA 1.20 (0.65, 2.22) 0.558 1.30 (0.70, 2.40) 0.402
Opsonising antibodies to placental-binding VSA 1.64 (0.91, 2.98) 0.102 1.82 (0.99, 3.36) 0.054
Opsonising antibodies to non-placental-binding VSA 1.31 (0.73, 2.35) 0.363 1.74 (0.97, 3.13) 0.065
MSP1 19kD 1.23 (0.69, 2.18) 0.488 1.27 (0.72, 2.25) 0.407
MSP2 1.47 (0.82, 2.64) 0.198 1.83 (1.01, 3.31) 0.046*
MSP3 0.59 (0.33, 1.05) 0.071 1.12 (0.65, 1.92) 0.691
EBA175 0.97 (0.55, 1.71) 0.913 1.14 (0.66, 1.99) 0.636
PfRh2 0.94 (0.54, 1.63) 0.818 1.05 (0.59, 1.85) 0.879
Schizont extract 1.51 (0.78, 2.92) 0.223 1.70 (0.90, 3.24) 0.104
Table 4 Association between  antibody tertiles at  enrolment and  small for  gestational age and  low length-for-age 
(LAZ <−2)
Data presented as odds ratio (95% confidence interval). Multivariate logistic regression analysis performed to determine the risk of giving birth to a child with SGA 
and LAZ <−2 among pregnant women in middle and high antibody tertile compared to women in the low antibody tertile. Analysis adjusted for gravidity, maternal 
age, HIV, bed net use, body mass index at enrolment, malaria microscopy at enrolment, socioeconomic status, study site, season at enrolment and supplementation 
groups
LAZ, length-for-age z-score; OR, odds ratio; 95% CI, 95% confidence interval; IgG, immunoglobulin G; VSA, variant surface antigens, MSP, merozoite surface protein; 
EBA175, erythrocyte binding homologue 175; PfRh2, Plasmodium falciparum reticulocyte binding homologue 2
Antibody type Small for gestational age Low length‑for‑age (LAZ <−2)
Middle compared 
to low antibody tertile
High compared to low 
antibody tertile
Middle compared 
to low antibody tertile
High compared to low 
antibody tertile
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
IgG to placental-binding VSA 0.74 (0.42, 1.31) 0.301 0.91 (0.52,1.60) 0.736 1.27 (0.62, 2.62) 0.513 1.05 (0.50, 2.21) 0.894
Opsonising antibodies to placental-
binding VSA
0.92 (0.54, 1.57) 0.757 0.78 (0.45, 1.35) 0.369 2.25 (1.14, 4.42) 0.019* 1.14 (0.53, 2.47) 0.734
Opsonising antibodies to non-placental-
binding VSA
1.34 (0.79, 2.28) 0.282 1.17 (0.67, 2.02) 0.584 1.29 (0.65, 2.56) 0.465 1.13 (0.56, 2.28) 0.735
MSP1 19kD 1.21 (0.71, 2.05) 0.476 0.93 (0.55, 1.59) 0.795 1.05 (0.54, 2.02) 0.889 0.75 (0.38, 1.48) 0.408
MSP2 1.12 (0.66, 1.89) 0.671 0.82 (0.48, 1.42) 0.486 0.97 (0.50, 1.90) 0.930 0.96 (0.48, 1.93) 0.918
MSP3 1.28 (0.75, 2.18) 0.358 1.65 (0.98, 2.80) 0.060 0.87 (0.44, 1.72) 0.682 1.28 (0.67, 2.46) 0.459
EBA175 1.62 (0.94, 2.75) 0.081 1.45 (0.85, 2.45) 0.172 0.88 (0.45, 1.72) 0.711 0.84 (0.43, 1.62) 0.608
PfRh2 1.26 (0.75, 2.13) 0.378 1.01 (0.59, 1.72) 0.979 1.18 (0.61, 2.29) 0.620 0.92 (0.46, 1.84) 0.815
Schizont extract 1.25 (0.68, 2.28) 0.469 1.44 (0.80, 2.61) 0.226 1.15 (0.54, 2.44) 0.724 1.27 (0.61, 2.63) 0.518
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residence, which may affect malaria exposure, but might 
also be markers of poverty and/or nutritional insecurity.
There was a weak association between antibodies to 
MSP2 and past placental malaria, and similar trends for 
antibody to schizont antigen and opsonizing antibody to 
both placental-binding and non-placental-binding para-
site lines. Past placental malaria is characterized by per-
sistent haemozoin deposits in fibrin in the placenta with 
no pRBCs [39], a sign of infection that has been cleared 
prior to delivery. Women with high antibody levels at 
study entry likely live in environments where they are at 
great risk of malaria infection, and this higher risk may 
persist in pregnancy despite use of IPTp and ITNs, and so 
will increase the likelihood they have experienced placen-
tal malaria at some point in pregnancy. Placental blood 
circulation is established at around 9–12 weeks gestation 
[40]. Infections occurring before study enrolment may 
increase antibodies to MSP2, while infections present at 
any time after 9–12 weeks’ gestation may affect the pla-
centa, but will be cleared by IPTp leaving residual pig-
ment. It is likely that the same women are at higher risk 
of malaria over both periods.
Antibodies to placental-binding VSA were not sig-
nificantly associated with improved newborn anthropo-
metrics unlike previous reports [9, 35, 41]. In previous 
reports the mothers were secundigravidae [9], secundi-
gravidae with placental malaria and HIV [41] or women 
with chronic placental infection [35] and antibody levels 
were measured at delivery rather than in early pregnancy. 
Rather than demonstrating population-wide associations 
between malaria antibodies and birthweight (as stud-
ied here), most published studies have been restricted 
to women of a specific gravidity or HIV and/or malaria 
infection status [12, 30, 33]. Further prospective studies 
of these high-risk groups for associations between immu-
nity and outcome may be indicated.
There was an unexpected negative association between 
opsonizing antibody to the placental-binding parasite 
line and newborn length, seen when women in the mid-
dle and low antibody groups were compared. The cause 
of this is not clear, and there was no similar trend when 
women with high and low antibody response were com-
pared, nor was there a similar association between levels 
of IgG antibody to VSA of the placental-binding line and 
newborn length.
Endpoints such as maternal haemoglobin, birth weight, 
SGA and newborn length are multifactorial in aetiol-
ogy, and estimating the proportion of each attributable 
to malaria is challenging. Study participants received 
protection against malaria with two doses of IPTp with 
sulphadoxine pyrimethamine and ITNs, limiting their 
exposure to malaria after enrolment, decreasing their risk 
of anaemia and LBW, and improving birth weights [42]. 
Only 3% of women had active malaria infection on pla-
cental histology, and malaria prevalence by RDT was 8%, 
a decrease from 23% at first antenatal visit (M Nkhoma, 
in submission). Malaria in later pregnancy was associ-
ated with low birth weight and decreased fetal size (M 
Nkhoma, in submission), but in settings where malaria 
prevalence is low (such as when malaria transmis-
sion falls), the attributable fractions of low birth weight 
and other outcomes due to malaria may be low, and it 
may therefore become increasingly difficult to iden-
tify immune responses to malaria that protect against 
adverse pregnancy outcomes.
Strengths of the study included a large sample size, of 
over 1000 women; analysis of a range of antibody meas-
ures; and extensive clinical data. Linear and logistic 
regression analyses were used to adjust for factors associ-
ated with the input and/or dependent variables of inter-
est. Study limitations included few women with preterm 
delivery (because only women with a 36 gw visit were 
included), preventing an investigation of whether anti-
body protects against preterm delivery; measurement 
of antibody responses to single parasite isolates of each 
phenotype, and single variants of each of a modest num-
ber of merozoite proteins; and measurement of a single 
functional role of antibodies (opsonization of pRBC for 
phagocytosis). Apart from preterm delivery and associ-
ated lower birth weights, other characteristics more com-
mon in excluded women included being primigravid, 
and higher rates of malaria infection by PCR at enrol-
ment. This may have limited our power to find protective 
associations. Quantitating antibody to other placental-
binding parasite isolates, [43] and understanding other 
antibody functions, such as merozoite opsonization [44] 
or complement fixation [45] could be beneficial in future 
studies. HIV was included as a co-factor, but helminth 
and bacterial infections which are prevalent among 
Malawian pregnant women [46–48] were not evaluated, 
which may have influenced certain analyses such as asso-
ciation with haemoglobin concentration. To dissect the 
determinants of aetiologically-complex pregnancy out-
comes such as maternal haemoglobin, birth size, or pre-
term delivery, a broad range of comorbid conditions may 
need to be addressed.
The study findings suggest that antibody to pregnancy-
specific parasite isolates, measured using two different 
approaches, may be associated with protection from 
malarial anaemia, whereas antibodies to merozoite-spe-
cific antigens are not. Further studies that prospectively 
evaluate pregnancy-specific and more general measures 
of malaria antibody, under a range of transmission set-
tings, will be required to determine whether one or more 
measures may identify women at risk with sufficient sen-
sitivity and specificity to be considered as a screening tool 
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for high-risk pregnancies in the future. The lack of evi-
dence that naturally-acquired antibodies to one placen-
tal binding parasite line were associated with improved 
fetal growth may reflect the relatively modest impact of 
malaria on birth weight in this cohort. Demonstration 
that induction of antibodies by a VAR2CSA based vac-
cine improves pregnancy outcomes would require care-
ful selection of target populations in which malaria is a 
major contributor to adverse pregnancy outcomes.
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